MedTrace Logo

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-08-03

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough

Conditions

  • Chronic Refractory Cough

Interventions

DRUG

BLU-5937

Four escalating doses of BLU-5937 administered BID over the course of the study

DRUG

Placebo

Matching placebo for BLU-5937

Sponsors & Collaborators

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Principal Investigators

  • Jacky Smith, MD, Ph.D. · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2020-04-23
Completion
2020-04-23
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979638 on ClinicalTrials.gov